480439-17-6

Basic information

• Product Name: 2-SEC-BUTYLPHENYL ISOCYANATE 97
• Synonyms: Benzene, 1-isocyanato-2-(1-methylpropyl)- (9CI);2-SEC-BUTYLPHENYL ISOCYANATE 97
• CAS NO: 480439-17-6
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.22702
• Product Categories: ISOCYANATE;Isocyanates;Nitrogen Compounds;Organic Building Blocks
• Mol File: 480439-17-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 219-220 °C(lit.)
• Flash Point: 195 °F
• Appearance: /
• Density: 0.999 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.044mmHg at 25°C
• Refractive Index: n20/D 1.5200(lit.)
• CAS DataBase Reference: 2-SEC-BUTYLPHENYL ISOCYANATE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 2-SEC-BUTYLPHENYL ISOCYANATE 97(480439-17-6)
• EPA Substance Registry System: 2-SEC-BUTYLPHENYL ISOCYANATE 97(480439-17-6)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-42
• Safety Statements: 23-26-36
• WGK Germany: 3
• Hazardous Substances Data: 480439-17-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H13NO/c1-3-9(2)10-6-4-5-7-11(10)12-8-13/h4-7,9H,3H2,1-2H3

Upstream product

• 75-44-5 phosgene 
• 55751-54-7 2-sec-butylaniline 

Downstream Products

• 1202526-38-2 1-(2-sec-butylphenyl)-3-(2-hydroxy-4-nitrophenyl)urea 
• 1400979-97-6 1-(benzyloxy)-4-sec-butyl-1H-benzo[d]imidazol-2(3H)-one 
• 1400979-84-1 1-(benzyloxy)-3-(2-sec-butylphenyl)urea 

Relevant articles and documents

Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ

Amyloid β (Aβ), a key molecule in the pathogenesis of Alzheimer's disease (AD), is derived from the amyloid precursor protein (APP) by sequential proteolysis via β- and γ-secretases. Because of their role in generation of Aβ, these enzymes have emerged as important therapeutic targets for AD. In the case of γ-secretase, progress has been made towards designing potent inhibitors with suitable pharmacological profiles. Direct γ-secretase inhibitors are being evaluated in clinical trials and new strategies are being explored to block γ-secretase activity indirectly as well. In this regard, we have previously reported an indirect regulation of γ-secretase through antagonism of CXCR2, a G-protein coupled receptor (GPCR). We demonstrated that N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea (SB225002), a selective inhibitor of CXCR2 also plays a role in an indirect inhibition of γ-secretase. Furthermore, we reported a ～5-fold difference in the selective inhibition of APP versus Notch processing via γ-secretase following treatment with SB225002. Herein we describe the synthesis and optimization of SB225002. By determination of the structure-activity relationship (SAR), we derived small molecules that inhibit Aβ40 production with IC50 values in the sub-micromolar range in a cell-based assay and also validated the potential of CXCR2 as a new target for therapeutic intervention in AD.